| Year |
Citation |
Score |
| 2024 |
Amsalem D, Jankowski SE, Yanos P, Yang LH, Markowitz JC, Rogers RT, Stroup TS, Dixon LB, Pope LG. Randomized Controlled Trial of a Brief Video Intervention to Reduce Self-Stigma of Mental Illness. The Journal of Clinical Psychiatry. 85. PMID 38451170 DOI: 10.4088/JCP.23m15034 |
0.394 |
|
| 2023 |
Amsalem D, Rogers RT, Stroup TS, Dixon L, Pope LG. Self-stigma among people with serious mental illnesses: The use of focus groups to inform the development of a brief video intervention. Psychiatric Rehabilitation Journal. PMID 37227841 DOI: 10.1037/prj0000570 |
0.517 |
|
| 2022 |
Stefancic A, Rogers RT, Styke S, Xu X, Buchsbaum R, Nossel I, Cabassa LJ, Stroup TS, Kimhy D. Development of the First Episode Digital Monitoring mHealth Intervention for People With Early Psychosis: Qualitative Interview Study With Clinicians. Jmir Mental Health. 9: e41482. PMID 36331539 DOI: 10.2196/41482 |
0.657 |
|
| 2022 |
Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, ... ... Stroup TS, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. PMID 35396580 DOI: 10.1038/s41586-022-04434-5 |
0.495 |
|
| 2021 |
Bareis N, Olfson M, Wall M, Stroup TS. Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. Psychiatric Services (Washington, D.C.). appips202000932. PMID 34587788 DOI: 10.1176/appi.ps.202000932 |
0.402 |
|
| 2021 |
Olfson M, Stroup TS, Huang C, Wall MM, Crystal S, Gerhard T. Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. Jama Psychiatry. PMID 34037667 DOI: 10.1001/jamapsychiatry.2021.0841 |
0.322 |
|
| 2021 |
Rolin SA, Bareis N, Bradford JM, Rotter M, Rosenfeld B, Pauselli L, Compton MT, Stroup TS, Appelbaum PS, Dixon LB. Violence risk assessment for young adults receiving treatment for early psychosis. International Journal of Law and Psychiatry. 76: 101701. PMID 33887604 DOI: 10.1016/j.ijlp.2021.101701 |
0.409 |
|
| 2021 |
Stroup TS, Olfson M, Huang C, Wall MM, Goldberg T, Devanand DP, Gerhard T. Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. Jama Psychiatry. PMID 33688938 DOI: 10.1001/jamapsychiatry.2021.0042 |
0.333 |
|
| 2020 |
Beck-Felts K, Goodman M, Ospina LH, Wall M, McEvoy J, Jarskog LF, Ballon JS, Bartels MN, Buchsbaum R, Sloan RP, Stroup TS, Kimhy D. Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. Trials. 21: 871. PMID 33087170 DOI: 10.1186/s13063-020-04788-z |
0.652 |
|
| 2020 |
Nakonezny PA, Lindow JC, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Byerly MJ. A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Schizophrenia Research. 220: 92-97. PMID 32269005 DOI: 10.1016/j.schres.2020.03.053 |
0.332 |
|
| 2019 |
Ospina LH, Wall M, Jarskog LF, Ballon JS, McEvoy J, Bartels MN, Buchsbaum R, Sloan RP, Stroup TS, Kimhy D. Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. Journal of Psychiatry and Brain Science. 4. PMID 31938726 DOI: 10.20900/jpbs.20190020 |
0.621 |
|
| 2019 |
Stroup TS. Clozapine and Evidence-Based Psychopharmacology for Schizophrenia. Jama Psychiatry. 76: 1007-1008. PMID 31365031 DOI: 10.1001/jamapsychiatry.2019.1656 |
0.445 |
|
| 2019 |
Stroup TS, Gerhard T, Crystal S, Huang C, Tan Z, Wall MM, Mathai C, Olfson M. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. Jama Psychiatry. PMID 30785609 DOI: 10.1001/Jamapsychiatry.2018.4489 |
0.46 |
|
| 2018 |
Stroup TS, Gerhard T, Crystal S, Huang C, Tan Z, Wall MM, Mathai CM, Olfson M. Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. Psychiatric Services (Washington, D.C.). appips201700356. PMID 29606075 DOI: 10.1176/Appi.Ps.201700356 |
0.383 |
|
| 2018 |
Jarskog L, Stroup TS. 261. Metformin and 5-HT2C Agonist Lorcaserin for Weight Loss in Schizophrenia Biological Psychiatry. 83: S105-S106. DOI: 10.1016/J.Biopsych.2018.02.280 |
0.456 |
|
| 2017 |
Stroup TS, Lieberman JA. Raising the standard of care for schizophrenia is an achievable goal. The Australian and New Zealand Journal of Psychiatry. 4867417700277. PMID 28374601 DOI: 10.1177/0004867417700277 |
0.517 |
|
| 2016 |
Vakhrusheva J, Marino B, Stroup TS, Kimhy D. Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits. Current Behavioral Neuroscience Reports. 3: 165-175. PMID 27766192 DOI: 10.1007/S40473-016-0077-2 |
0.669 |
|
| 2016 |
Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Psychiatric Services (Washington, D.C.). appips201500447. PMID 27247177 DOI: 10.1176/Appi.Ps.201500447 |
0.339 |
|
| 2016 |
Carruthers J, Radigan M, Erlich MD, Gu G, Wang R, Frimpong EY, Essock SM, Olfson M, Castillo EG, Miller GA, Sederer LI, Stroup TS. An Initiative to Improve Clozapine Prescribing in New York State. Psychiatric Services (Washington, D.C.). appips201500493. PMID 26725299 DOI: 10.1176/appi.ps.201500493 |
0.379 |
|
| 2016 |
Olfson M, Gerhard T, Crystal S, Stroup TS. Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. Psychiatric Services (Washington, D.C.). 67: 152. PMID 26522679 DOI: 10.1176/Appi.Ps.201500324 |
0.357 |
|
| 2015 |
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. The American Journal of Psychiatry. appiajp201515030332. PMID 26541815 DOI: 10.1176/Appi.Ajp.2015.15030332 |
0.427 |
|
| 2015 |
Dixon LB, Stroup TS. Medications for first-episode psychosis: making a good start. The American Journal of Psychiatry. 172: 209-11. PMID 25727529 DOI: 10.1176/Appi.Ajp.2014.14111465 |
0.644 |
|
| 2014 |
Stroup TS. What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia? The Journal of Clinical Psychiatry. 75: 1261-2. PMID 25470086 DOI: 10.4088/JCP.14com09518 |
0.449 |
|
| 2014 |
Stroup TS, McEvoy JP, Hamer RM. Antipsychotic medications for schizophrenia--reply. Jama. 312: 1469. PMID 25291588 DOI: 10.1001/jama.2014.10112 |
0.425 |
|
| 2014 |
Williams JM, Stroup TS, Brunette MF, Raney LE. Tobacco use and mental illness: a wake-up call for psychiatrists. Psychiatric Services (Washington, D.C.). 65: 1406-8. PMID 25270381 DOI: 10.1176/Appi.Ps.201400235 |
0.302 |
|
| 2014 |
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. Jama. 311: 1978-87. PMID 24846035 DOI: 10.1001/jama.2014.4310 |
0.469 |
|
| 2014 |
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatric Services (Washington, D.C.). 65: 186-92. PMID 24233347 DOI: 10.1176/Appi.Ps.201300180 |
0.52 |
|
| 2013 |
Stroup TS, Dixon LB. The enduring challenge of antipsychotic non-adherence. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 12: 236-7. PMID 24096787 DOI: 10.1002/wps.20079 |
0.477 |
|
| 2013 |
Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, ... ... Stroup TS, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 45: 984-94. PMID 23933821 DOI: 10.1038/Ng.2711 |
0.379 |
|
| 2013 |
Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 170: 1032-40. PMID 23846733 DOI: 10.1176/Appi.Ajp.2013.12010127 |
0.58 |
|
| 2013 |
Ballon J, Stroup TS. Polypharmacy for schizophrenia. Current Opinion in Psychiatry. 26: 208-13. PMID 23318662 DOI: 10.1097/Yco.0B013E32835D9Efb |
0.445 |
|
| 2013 |
Stroup TS. The need to determine the best options for people with schizophrenia that is unresponsive to treatment. Revista De Psiquiatria Y Salud Mental. 6: 1-3. PMID 23084800 DOI: 10.1016/j.rpsm.2012.06.003 |
0.438 |
|
| 2013 |
Nussbaum AM, Stroup TS. Drug information update: paliperidone palmitate for schizophrenia The Psychiatrist. 37: 164-166. DOI: 10.1192/PB.BP.113.042739 |
0.448 |
|
| 2012 |
Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Schizophrenia Bulletin. 38: 1124-7. PMID 22966147 DOI: 10.1093/schbul/sbs099 |
0.444 |
|
| 2012 |
Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. The Cochrane Database of Systematic Reviews. CD008296. PMID 22696377 DOI: 10.1002/14651858.CD008296.pub2 |
0.356 |
|
| 2012 |
Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The Journal of Clinical Psychiatry. 73: 526-32. PMID 22579152 DOI: 10.4088/Jcp.11M07162 |
0.315 |
|
| 2012 |
Stroup TS, A Lieberman J, S Swartz M, McEvoy JP. Comparative effectiveness of antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience. 2: 373-9. PMID 22033808 DOI: 10.31887/DCNS.2000.2.4/tstroup |
0.446 |
|
| 2012 |
Aberg K, Adkins DE, Liu Y, McClay JL, Bukszár J, Jia P, Zhao Z, Perkins D, Stroup TS, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide association study of antipsychotic-induced QTc interval prolongation. The Pharmacogenomics Journal. 12: 165-72. PMID 20921969 DOI: 10.1038/Tpj.2010.76 |
0.437 |
|
| 2012 |
Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, Hsiao J, Lieberman J. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research. 7: 103-11. PMID 20528436 DOI: 10.1586/14737167.7.2.103 |
0.59 |
|
| 2011 |
Davis SM, Stroup TS, Koch GG, Davis CE, Rosenheck RA, Lieberman JA. Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. Statistics in Biopharmaceutical Research. 3: 253-265. PMID 31031886 DOI: 10.1198/Sbr.2011.10013 |
0.43 |
|
| 2011 |
Tiwari HK, Patki A, Lieberman J, Stroup TS, Allison DB, Leibel RL, Chung WK. Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Frontiers in Genetics. 2: 56. PMID 22039372 DOI: 10.3389/Fgene.2011.00056 |
0.453 |
|
| 2011 |
Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RSE, McEvoy JP, Stroup TS. Substance use and schizophrenia: Adverse correlates in the CATIE study sample Schizophrenia Research. 132: 177-182. PMID 21872443 DOI: 10.1016/j.schres.2011.07.032 |
0.386 |
|
| 2011 |
Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? The American Journal of Psychiatry. 168: 770-5. PMID 21813492 DOI: 10.1176/Appi.Ajp.2011.11010039 |
0.501 |
|
| 2011 |
Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry. 168: 947-56. PMID 21768610 DOI: 10.1176/Appi.Ajp.2011.10111609 |
0.427 |
|
| 2011 |
Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The American Journal of Psychiatry. 168: 831-9. PMID 21572163 DOI: 10.1176/Appi.Ajp.2011.08121844 |
0.354 |
|
| 2011 |
Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophrenia Research. 130: 47-52. PMID 21561740 DOI: 10.1016/J.Schres.2011.04.012 |
0.513 |
|
| 2011 |
Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, Adler L, Byerly M, Caroff S, Csernansky J, D'Souza C, Manschreck T, McEvoy J, Miller A, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy American Journal of Psychiatry. 168: 702-708. PMID 21536693 DOI: 10.1176/Appi.Ajp.2011.10060908 |
0.393 |
|
| 2011 |
Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research. 128: 166-70. PMID 21334853 DOI: 10.1016/J.Schres.2011.01.022 |
0.544 |
|
| 2011 |
Stroup TS, Jarskog LF. No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differ. Evidence-Based Mental Health. 14: 25. PMID 21266622 DOI: 10.1136/ebmh.14.1.25 |
0.313 |
|
| 2011 |
Greenberg G, Rosenheck RA, Erickson SK, Desai RA, Stefanovics EA, Swartz M, Keefe RS, McEvoy J, Stroup TS. Criminal justice system involvement among people with schizophrenia. Community Mental Health Journal. 47: 727-36. PMID 21113799 DOI: 10.1007/s10597-010-9362-9 |
0.449 |
|
| 2011 |
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 616-26. PMID 21107309 DOI: 10.1038/Npp.2010.193 |
0.478 |
|
| 2011 |
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 75-80. PMID 20868641 DOI: 10.4088/Jcp.09M05258Gre |
0.563 |
|
| 2011 |
Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 295-303. PMID 20816031 DOI: 10.4088/Jcp.09M05793Yel |
0.536 |
|
| 2011 |
Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular Psychiatry. 16: 321-32. PMID 20195266 DOI: 10.1038/Mp.2010.14 |
0.502 |
|
| 2011 |
Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin. 37: 1057-65. PMID 20194249 DOI: 10.1093/Schbul/Sbq010 |
0.311 |
|
| 2011 |
Davis SM, Stroup TS, Koch GG, Davis CE, Rosenheck RA, Lieberman JA. Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study Statistics in Biopharmaceutical Research. 3: 253-265. DOI: 10.1198/sbr.2011.10013 |
0.432 |
|
| 2011 |
Geddes JR, Stroup TS, Lieberman JA. Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia Schizophrenia: Third Edition. 525-539. DOI: 10.1002/9781444327298.ch25 |
0.568 |
|
| 2010 |
Stroup TS, Jarskog LF. Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. Evidence-Based Mental Health. 13: 53. PMID 21856616 DOI: 10.1136/ebmh.13.2.53 |
0.448 |
|
| 2010 |
Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, van den Oord E, Sullivan PF. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1115-7. PMID 20468059 DOI: 10.1002/Ajmg.B.31077 |
0.528 |
|
| 2010 |
Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, Stroup TS, Sullivan PF. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 336-40. PMID 19475583 DOI: 10.1002/Ajmg.B.30981 |
0.564 |
|
| 2010 |
Tsai J, Stroup TS, Rosenheck RA. Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study Journal of Community Psychology. 39: 76-88. DOI: 10.1002/Jcop.20418 |
0.5 |
|
| 2009 |
McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, ... ... Stroup TS, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics. 41: 1223-7. PMID 19855392 DOI: 10.1038/Ng.474 |
0.45 |
|
| 2009 |
Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry. 66: 1013-22. PMID 19640511 DOI: 10.1016/J.Biopsych.2009.06.005 |
0.552 |
|
| 2009 |
Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. The American Journal of Psychiatry. 166: 583-90. PMID 19369318 DOI: 10.1176/Appi.Ajp.2008.08081218 |
0.405 |
|
| 2009 |
Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA. The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry. 31: 1-7. PMID 19134502 DOI: 10.1016/J.Genhosppsych.2008.09.012 |
0.546 |
|
| 2009 |
Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 107: 1-12. PMID 19027269 DOI: 10.1016/J.Schres.2008.10.011 |
0.63 |
|
| 2009 |
Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan Pf. Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903228991 |
0.543 |
|
| 2009 |
Sullivan PF, Lin D, Tzeng J, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Erratum: Genomewide association for schizophrenia in the CATIE study: results of stage 1 Molecular Psychiatry. 14: 1144-1144. DOI: 10.1038/Mp.2008.74 |
0.538 |
|
| 2008 |
Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Extrapyramidal side-effects of antipsychotics in a randomised trial. The British Journal of Psychiatry : the Journal of Mental Science. 193: 279-88. PMID 18827289 DOI: 10.1192/Bjp.Bp.108.050088 |
0.54 |
|
| 2008 |
Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research. 105: 175-87. PMID 18775645 DOI: 10.1016/J.Schres.2008.07.006 |
0.533 |
|
| 2008 |
Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 193: 37-43. PMID 18700216 DOI: 10.1192/Bjp.Bp.107.042630 |
0.628 |
|
| 2008 |
Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research. 103: 104-9. PMID 18534821 DOI: 10.1016/J.Schres.2008.04.023 |
0.627 |
|
| 2008 |
Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA. What CATIE found: results from the schizophrenia trial. Psychiatric Services (Washington, D.C.). 59: 500-6. PMID 18451005 DOI: 10.1176/Ps.2008.59.5.500 |
0.59 |
|
| 2008 |
Nussbaum A, Stroup TS. Paliperidone for schizophrenia. The Cochrane Database of Systematic Reviews. CD006369. PMID 18425951 DOI: 10.1002/14651858.CD006369.pub2 |
0.359 |
|
| 2008 |
Nussbaum AM, Stroup TS. Paliperidone for treatment of schizophrenia. Schizophrenia Bulletin. 34: 419-22. PMID 18375569 DOI: 10.1093/Schbul/Sbn015 |
0.353 |
|
| 2008 |
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Molecular Psychiatry. 13: 570-84. PMID 18347602 DOI: 10.1038/Mp.2008.25 |
0.52 |
|
| 2008 |
Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 1298-300. PMID 18286587 DOI: 10.1002/Ajmg.B.30727 |
0.559 |
|
| 2008 |
Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 101: 273-86. PMID 18258416 DOI: 10.1016/J.Schres.2007.12.487 |
0.533 |
|
| 2008 |
Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, Lieberman J. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The Journal of Behavioral Health Services & Research. 35: 215-25. PMID 18246429 DOI: 10.1007/S11414-007-9101-3 |
0.594 |
|
| 2008 |
Stroup TS, Geddes JR. Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. Schizophrenia Bulletin. 34: 266-74. PMID 18245060 DOI: 10.1093/Schbul/Sbm156 |
0.429 |
|
| 2008 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research. 100: 39-52. PMID 18191383 DOI: 10.1016/J.Schres.2007.11.034 |
0.6 |
|
| 2008 |
Campbell DB, Ebert PJ, Skelly T, Stroup TS, Lieberman J, Levitt P, Sullivan PF. Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia Biological Psychiatry. 63: 32-41. PMID 17588543 DOI: 10.1016/J.Biopsych.2007.04.018 |
0.618 |
|
| 2007 |
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry. 68: 1751-62. PMID 18052569 DOI: 10.4088/Jcp.V68N1115 |
0.438 |
|
| 2007 |
Jayaram MB, Hosalli PM, Stroup TS. Risperidone versus olanzapine for treatment of schizophrenia Schizophrenia Bulletin. 33: 1274-1276. PMID 17921477 DOI: 10.1093/schbul/sbm101 |
0.461 |
|
| 2007 |
Kim SY, Appelbaum PS, Swan J, Stroup TS, McEvoy JP, Goff DC, Jeste DV, Lamberti JS, Leibovici A, Caine ED. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. The British Journal of Psychiatry : the Journal of Mental Science. 191: 38-43. PMID 17602123 DOI: 10.1192/Bjp.Bp.106.033324 |
0.473 |
|
| 2007 |
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633 |
0.594 |
|
| 2007 |
Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. AKT1 and neurocognition in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 41: 169-77. PMID 17464696 DOI: 10.1080/00048670601109956 |
0.62 |
|
| 2007 |
Stroup TS. Heterogeneity of treatment effects in schizophrenia. The American Journal of Medicine. 120: S26-31. PMID 17403379 DOI: 10.1016/J.Amjmed.2007.02.005 |
0.563 |
|
| 2007 |
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428 |
0.625 |
|
| 2007 |
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/Ajp.2007.164.3.415 |
0.604 |
|
| 2007 |
Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. NCAM1 and neurocognition in schizophrenia. Biological Psychiatry. 61: 902-10. PMID 17161382 DOI: 10.1016/J.Biopsych.2006.07.036 |
0.581 |
|
| 2007 |
Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? International Journal of Clinical Practice. 60: 933-40. PMID 16893436 DOI: 10.1111/J.1742-1241.2006.01044.X |
0.495 |
|
| 2007 |
Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study Clinical Schizophrenia and Related Psychoses. 1: 69-72. DOI: 10.3371/Csrp.1.1.6 |
0.566 |
|
| 2006 |
Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. The American Journal of Psychiatry. 163: 2090-5. PMID 17151159 DOI: 10.1176/Ajp.2006.163.12.2090 |
0.461 |
|
| 2006 |
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080 |
0.619 |
|
| 2006 |
Adams CE, Tharyan P, Coutinho ES, Stroup TS. The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. The British Journal of Psychiatry : the Journal of Mental Science. 189: 391-2. PMID 17077426 DOI: 10.1192/Bjp.Bp.106.029983 |
0.453 |
|
| 2006 |
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine. 355: 1525-38. PMID 17035647 DOI: 10.1056/Nejmoa061240 |
0.473 |
|
| 2006 |
Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research. 86: 15-22. PMID 16884895 DOI: 10.1016/J.Schres.2006.06.026 |
0.594 |
|
| 2006 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Cañive JM, Lieberman JA. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services (Washington, D.C.). 57: 1110-6. PMID 16870961 DOI: 10.1176/Ps.2006.57.8.1110 |
0.553 |
|
| 2006 |
Stroup TS. Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. Evidence-Based Mental Health. 9: 70. PMID 16868189 DOI: 10.1136/Ebmh.9.3.70 |
0.353 |
|
| 2006 |
Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry. 63: 490-9. PMID 16651506 DOI: 10.1001/Archpsyc.63.5.490 |
0.582 |
|
| 2006 |
Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, ... ... Stroup TS, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072 |
0.598 |
|
| 2006 |
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611 |
0.608 |
|
| 2006 |
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600 |
0.601 |
|
| 2006 |
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease. 194: 164-72. PMID 16534433 DOI: 10.1097/01.Nmd.0000202575.79453.6E |
0.532 |
|
| 2006 |
Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews. Drug Discovery. 5: 133-46. PMID 16518380 DOI: 10.1038/Nrd1956 |
0.476 |
|
| 2006 |
Lieberman JA, Stroup TS, McEVOY JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD. Dr. Lieberman and Colleagues Reply American Journal of Psychiatry. 163: 555-556. DOI: 10.1176/Appi.Ajp.163.3.555-A |
0.351 |
|
| 2005 |
Stroup TS, Appelbaum PS. Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Schizophrenia Bulletin. 32: 147-52. PMID 16282635 DOI: 10.1093/Schbul/Sbj026 |
0.449 |
|
| 2005 |
Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 80: 45-53. PMID 16198088 DOI: 10.1016/J.Schres.2005.08.010 |
0.537 |
|
| 2005 |
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 353: 1209-23. PMID 16172203 DOI: 10.1056/Nejmoa051688 |
0.507 |
|
| 2005 |
Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research. 80: 33-43. PMID 16171976 DOI: 10.1016/J.Schres.2005.07.034 |
0.635 |
|
| 2005 |
Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research. 80: 9-18. PMID 16125372 DOI: 10.1016/J.Schres.2005.07.015 |
0.58 |
|
| 2004 |
Stroup TS, McEvoy JP, Lieberman JA. Revised PORT recommendations Schizophrenia Bulletin. 30: 609-611. PMID 15631251 DOI: 10.1093/Oxfordjournals.Schbul.A007106 |
0.591 |
|
| 2004 |
Bradford DW, Stroup TS. Schizophrenia, drug therapy, and monitoring. The New England Journal of Medicine. 350: 415-6. PMID 14736938 DOI: 10.1056/NEJM200401223500420 |
0.373 |
|
| 2003 |
Lieberman JA, Stroup TS. Schizophrenia, VI: Treatments The American Journal of Psychiatry. 160: 1748. PMID 14514482 DOI: 10.1176/Appi.Ajp.160.10.1748 |
0.626 |
|
| 2003 |
Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial Schizophrenia Bulletin. 29: 33-43. PMID 12908659 DOI: 10.1093/Oxfordjournals.Schbul.A006989 |
0.525 |
|
| 2003 |
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin. 29: 15-31. PMID 12908658 DOI: 10.1093/Oxfordjournals.Schbul.A006986 |
0.599 |
|
| 2003 |
Lieberman JA, Stroup TS. Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care? Schizophrenia Bulletin. 29: 1-6. PMID 12908656 DOI: 10.1093/Oxfordjournals.Schbul.A006979 |
0.495 |
|
| 2000 |
Phillips MR, Li Y, Stroup TS, Xin L. Causes of schizophrenia reported by patients' family members in China. The British Journal of Psychiatry : the Journal of Mental Science. 177: 20-5. PMID 10945083 DOI: 10.1192/Bjp.177.1.20 |
0.397 |
|
| 2000 |
Stroup TS, Gilmore JH, Jarskog LF. Management of Medical Illness in Persons With Schizophrenia Psychiatric Annals. 30: 35-40. DOI: 10.3928/0048-5713-20000101-10 |
0.469 |
|
| Show low-probability matches. |